Experts discuss rising PSA despite negative PSMA PET imaging and review how surveillance imaging ultimately identified an early-stage primary lung adenocarcinoma.
Read More
Dr. Sherief H. Gamie reviews the EMPIRE-2 trial and discusses how PSMA PET and F-18 fluciclovine PET influence radiation planning for men with biochemical recurrence after radical prostatectomy. The discussion also explores emerging tracers and individualized imaging strategies.
Read More
Extended nodal radiotherapy improves long-term outcomes in prostate cancer recurrence beyond PET-visible disease.
Read More
The management of prostate cancer is moving away from the customary reliance on hormone suppression (ADT) at metastatic recurrence. New treatments seek to avoid the adverse effects of testosterone suppression in biochemically recurrent disease.
Read More
Early salvage radiation improves outcomes after prostatectomy while preserving quality of life through selective treatment.
Read More